One-Shot cancer treatment trial seeks to reprogram immune system from within
Disease control
Not yet recruiting
This early-stage study is testing the safety of an experimental therapy called DIT101 for adults whose blood cancers have returned or not responded to standard treatments. DIT101 is a one-time infusion designed to instruct the body's own immune system to create cancer-fighting ce…
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC